CATCH ALL - Molecular Leukemia Board

Personalized treatment options for adults and children with acute lymphoblastic leukemia (ALL)

In recent years, complex immunochemotherapy strategies have been standardized for both adult and pediatric patients in large-scale studies. Although this has improved the prognosis across all age groups, some patients remain refractory to therapy or experience a relapse. Adults and T-ALL patients are particularly affected by this. In this situation, strategies for advanced lines of therapy are less uniformly defined.

The goal of the CATCH ALL Molecular Leukemia Board is to subject pediatric and adult patients to an interdisciplinary discussion involving teams from the clinic as well as the CATCH ALL clinical research group, the pediatric study group (ALL-BFM), and the adult study group (GMALL). This interdisciplinary and cross-age approach is intended to promote individualized treatment plans and study enrollment across the region.

The CATCH ALL Board:

Is open to participating centers in the study groups
Allows centers to enroll their own patients
Offers comprehensive molecular characterization of leukemias and cross-age subtyping (RNA-Seq, SNP arrays, exome sequencing, and methylation arrays)